Metabolic roles of endocrine fibroblast growth factors.

Curr Opin Pharmacol

Division of Diabetes Endocrinology and Metabolism, Hammersmith Hospital Campus, Imperial College, London W12 0NN, UK. Electronic address:

Published: December 2015

Considerable effort is currently being devoted to understanding the physiological and pharmacological action of the endocrine fibroblast growth factors (FGFs). These three proteins (FGF15/19, FGF21 and FGF23) act in a tissue-specific manner through a membrane-complex consisting of an FGF-receptor and α/βKlotho. FGF15/19 is produced in the intestine and regulates postprandial liver metabolism and gallbladder filling. FGF21 is largely liver-derived and co-ordinates adaptive changes in response to nutritional and physiological stresses. FGF23 signals from the bone to the kidney to maintain phosphate homeostasis. In pharmacological settings, FGF15/19, FGF21, and the prototypical FGF1, potentially represent novel treatments for obesity and diabetes. This review summarises the recent advances in our understanding of the biology of these important metabolic regulators.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2015.09.014DOI Listing

Publication Analysis

Top Keywords

endocrine fibroblast
8
fibroblast growth
8
growth factors
8
fgf15/19 fgf21
8
metabolic roles
4
roles endocrine
4
factors considerable
4
considerable effort
4
effort currently
4
currently devoted
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!